American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 967-988 , December 2007

Treatment of Peritoneal Dialysis–Associated Peritonitis: A Systematic Review of Randomized Controlled Trials

  • Kathryn J. Wiggins, MBBS

      Affiliations

    • Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia
    • Corresponding Author InformationAddress correspondence to Kathryn J. Wiggins, MBBS(Hons), Department of Nephrology, St Vincent’s Hospital, PO Box 2900, Fitzroy, Victoria 3065, Australia.
    • ,
  • David W. Johnson, PhD, MBBS

      Affiliations

    • Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia
    • ,
  • Jonathan C. Craig, PhD, MBChB

      Affiliations

    • Centre for Kidney Research, NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Children’s Hospital at Westmead, School of Public Health, University of Sydney, Australia
    • ,
  • Giovanni F.M. Strippoli, MD, MPH, MM(Epi)

      Affiliations

    • Centre for Kidney Research, NHMRC Centre for Clinical Research Excellence in Renal Medicine, Cochrane Renal Group, Children’s Hospital at Westmead, School of Public Health, University of Sydney, Australia
    • Mario Negri Sud Consortium, Santa Maria Imbaro (Ch), Italy.

Received 10 April 2007 ,Accepted 23 August 2007.

References 

  1. Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs. 2002;25:249–260
  2. Bazzato G, Landini S, Coli U, Lucatello S, Fracasso A, Moracchiello M. A new technique of continuous ambulatory peritoneal dialysis (CAPD): Double-bag system for freedom to the patient and significant reduction of peritonitis. Clin Nephrol. 1980;13:251–254
  3. Monteon F, Correa-Rotter R, Paniagua R, et al. Prevention of peritonitis with disconnect systems in CAPD: A randomized controlled trial (The Mexican Nephrology Collaborative Study Group). Kidney Int. 1998;54:2123–2128
  4. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: A systematic review of randomized, controlled trials. J Am Soc Nephrol. 2004;15:2735–2746
  5. Kawaguchi Y. National comparisons: Optimal peritoneal dialysis outcomes among Japanese patients. Perit Dial Int. 1999;19(suppl 3):S9–S16
  6. Grunberg J, Verocay MC, Rebori A, et al. Twenty years’ pediatric chronic peritoneal dialysis in Uruguay: Patient and technique survival. Pediatr Nephrol. 2005;20:1315–1319
  7. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related infections. Perit Dial Int. 1994;14:137–144
  8. Juergensen PH, Gorban-Brennan N, Troidle L, Finkelstein FO. Racial differences and peritonitis in an urban peritoneal dialysis center. Adv Perit Dial. 2002;18:117–118
  9. Lim WH, Johnson DW, McDonald SP. Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: Analysis of ANZDATA. Nephrology (Carlton). 2005;10:192–197
  10. McDonald SP, Collins JF, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int. 2004;24:340–346
  11. Alves FR, Dantas RC, Lugon JR. Higher incidence of catheter-related infections in a tropical climate. Adv Perit Dial. 1993;9:244–247
  12. Szeto CC, Chow KM, Wong TY, Leung CB, Li PK. Influence of climate on the incidence of peritoneal dialysis-related peritonitis. Perit Dial Int. 2003;23:580–586
  13. Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkelstein FO. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis. 2003;42:350–354
  14. Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis. 2005;45:372–380
  15. Huang JW, Hung KY, Yen CJ, Wu KD, Tsai TJ. Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis. Nephrol Dial Transplant. 2001;16:604–607
  16. Smit W, van den Berg N, Schouten N, Aikens E, Struijk DG, Krediet RT. Free-water transport in fast transport status: A comparison between CAPD peritonitis and long-term PD. Kidney Int. 2004;65:298–303
  17. Ates K, Koc R, Nergizoglu G, et al. The longitudinal effect of a single peritonitis episode on peritoneal membrane transport in CAPD patients. Perit Dial Int. 2000;20:220–226
  18. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996;11:498–506
  19. Coles GA, Topley N. Long-term peritoneal membrane changes. Adv Ren Replace Ther. 2000;7:289–301
  20. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(suppl 4):S39–S47
  21. Rigby RJ, Hawley CM. Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant. 1998;13:154–159
  22. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol. 1996;7:2176–2182
  23. Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E. Peritoneal dialysis catheter removal for acute peritonitis: A retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis. 2004;43:103–111
  24. Heaf J. Underutilization of peritoneal dialysis. JAMA. 2004;291:740–742
  25. Pickering SJ, Fleming SJ, Bowley JA, et al. Urokinase: A treatment for relapsing peritonitis due to coagulase-negative staphylococci. Nephrol Dial Transplant. 1989;4:62–65
  26. Innes A, Burden RP, Finch RG, Morgan AG. Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: A double-blind clinical trial. Nephrol Dial Transplant. 1994;9:797–799
  27. Ejlersen E, Brandi L, Lokkegaard H, Ladefoged J, Kopp R, Haarh P. Is initial (24 hours) lavage necessary in treatment of CAPD peritonitis?. Perit Dial Int. 1991;11:38–42
  28. Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 Update. Perit Dial Int. 2005;25:107–131
  29. CARI: The CARI Guidelines (Caring for Australians with Renal Impairment). Nephrology (Carlton) 9. 2004;(suppl 3):S41–S106
  30. Passadakis P, Oreopoulos D. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2001;17:180–190
  31. Fielding RE, Clemenger M, Goldberg L, Brown EA. Treatment and outcome of peritonitis in automated peritoneal dialysis, using a once-daily cefazolin-based regimen. Perit Dial Int. 2002;22:345–349
  32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  33. Bennett-Jones D, Wass V, Mawson P. A comparison of intraperitoneal and intravenous/oral antibiotics in CAPD peritonitis. Perit Dial Bull. 1987;7:31–33
  34. Bailie GR, Morton R, Ganguli L, Keaney M, Waldek S. Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated gram-positive peritonitis?. Nephron. 1987;46:316–318
  35. Bennett-Jones DN, Russell GI, Barrett A. A comparison between oral ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. J Antimicrob Chemother. 1990;26(suppl F):S73–S76
  36. Cheng I, Lui S, Fang G, et al. A randomised prospective comparison of oral versus intraperitoneal ofloxacin as the primary treatment of CAPD peritonitis. Nephrology. 1997;3:431–435
  37. Cheng IK, Chan CY, Wong WT, et al. A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int. 1993;13(suppl 2):S351–S354
  38. Gucek A, Bren AF, Lindic J, Hergouth V, Mlinsek D. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients?. Adv Perit Dial. 1994;10:144–146
  39. Lye WC, Lee EJ, van der Straaten J. Intraperitoneal vancomycin/oral pefloxacin versus intraperitoneal vancomycin/gentamicin in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int. 1993;13(suppl 2):S348–S350
  40. Tapson JS, Orr KE, George JC, Stansfield E, Bint AJ, Ward MK. A comparison between oral ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. J Antimicrob Chemother. 1990;26(suppl F):S63–S71
  41. Cheng IK, Chan CY, Wong WT. A randomised prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int. 1991;11:27–30
  42. Chan MK, Cheng IK, Ng WS. A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1990;15:155–159
  43. Cheng IK, Fang GX, Chau PY, et al. A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD. Perit Dial Int. 1998;18:371–375
  44. Boeschoten EW, Rietra PJ, Krediet RT, Visser MJ, Arisz L. CAPD peritonitis: A prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother. 1985;16:789–797
  45. Bowley JA, Pickering SJ, Scantlebury AJ, Ackrill P, Jones DM. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. J Antimicrob Chemother. 1988;21(suppl A):S133–S139
  46. Friedland JS, Iveson TJ, Fraise AP, Winearls CG, Selkon JB, Oliver DO. A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother. 1990;26(suppl F):S77–S81
  47. Gucek A, Bren AF, Hergouth V, Lindic J. Cefazolin and netilmicin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. Adv Perit Dial. 1997;13:218–220
  48. Jimenez C, Selgas R, Sanchez S, et al. Initial empiric treatment of peritonitis in CAPD with vancomycin + tobramycin vs. vancomycin + cefotaxime in a CAPD unit. Nefrologia. 1996;16:569A;(abstr)
  49. Wale M, Finch R, Morgan A, Burden R, Holliday A. A prospective randomised trial of teicoplanin plus aztreonam versus cefuroxime in CAPD peritonitis. Int J Antimicrob Agents. 1992;1(suppl 1):S7–S14
  50. Were A, Marsden A, Tooth A, Ramsden R, Mistry C, Gokal R. Netilmycin and vancomycin in the treatment of peritonitis in CAPD patients. Clin Nephrol. 1992;37:2009–2213
  51. Flanigan MJ, Lim VS. Initial treatment of dialysis associated peritonitis: A controlled trial of vancomycin versus cefazolin. Perit Dial Int. 1991;11:31–37
  52. Wong KM, Chan YH, Cheung CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis. 2001;38:127–131
  53. Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis (The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS)). J Am Soc Nephrol. 1999;10:136–145
  54. Anwar N, Merchant M, Were T, Tooth A, Uttley L, Gokal R. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. Perit Dial Int. 1995;15:167–171
  55. Khairullah Q, Provenzano R, Tayeb J, Ahmad A, Balakrishnan R, Morrison L. Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patients. Perit Dial Int. 2002;22:339–344
  56. de Fijter CW, ter Wee PM, Oe LP, Verbrugh HA. Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C)APD-related peritonitis: A prospective randomized multicenter comparison (CIPPER trial). Perit Dial Int. 2001;21:480–486
  57. Leung CB, Szeto CC, Chow KM, et al. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis—A randomized controlled trial. Perit Dial Int. 2004;24:440–446
  58. Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: Effect on residual renal function. Kidney Int. 2005;68:2375–2380
  59. Lupo A, Rugiu C, Bernich P, et al. A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: Teicoplanin plus tobramycin versus cephalothin plus tobramycin. J Antimicrob Chemother. 1997;40:729–732
  60. Lye WC, Wong PL, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of single versus multidose gentamicin in the treatment of CAPD peritonitis. Adv Perit Dial. 1995;11:179–181
  61. Velasquez-Jones L, Sanchez-Aguilar J, Castelares G, et al. Efficacy of intraperitoneal vancomycin in children on continuous ambulatory peritoneal dialysis: Comparison of intermittent and continuous therapy. Bol Med Hospital Infantil Mexico. 1995;52:154–159
  62. Boyce NW, Wood C, Thomson NM, Kerr P, Atkins RC. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis—A prospective, randomized comparison of intermittent v continuous therapy. Am J Kidney Dis. 1988;12:304–306
  63. Gadallah MF, Tamayo A, Sandborn M, Ramdeen G, Moles K. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. Adv Perit Dial. 2000;16:233–236
  64. Tong MK, Leung KT, Siu YP, et al. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. J Nephrol. 2005;18:204–208
  65. Williams AJ, Boletis I, Johnson BF, et al. Tenckhoff catheter replacement or intraperitoneal urokinase: A randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis. Perit Dial Int. 1989;9:65–67
  66. Coban E, Ozdogan M, Tuncer M, Bozcuk H, Ersoy F. The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis. J Nephrol. 2004;17:427–430
  67. Milikin SMG, Keane WF. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int. 1991;11:252–260
  68. Kan GW, Thomas MA, Heath CH. A 12-month review of peritoneal dialysis-related peritonitis in Western Australia: Is empiric vancomycin still indicated for some patients?. Perit Dial Int. 2003;23:465–468
  69. Booranalertpaisarn V, Eiam-Ong S, Wittayalertpanya S, Kanjanabutr T, Na Ayudhya DP. Pharmacokinetics of ceftazidime in CAPD-related peritonitis. Perit Dial Int. 2003;23:574–579
  70. Deamer RL, Dial LK. The evolution of aminoglycoside therapy: A single daily dose. Am Fam Physician. 1996;53:1782–1786
  71. Grabe DW, Bailie GR, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis. 1999;33:111–117
  72. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19:65–70
  73. Manley HJ, Bailie GR. Treatment of peritonitis in APD: Pharmacokinetic principles. Semin Dial. 2002;15:418–421
  74. O’Brien PE, Tait N, Bushell M. Management of diffuse peritonitis by prolonged postoperative peritoneal lavage. Aust N Z J Surg. 1987;57:181–184
  75. Carozzi S, Nasini MG, Kunkl A, Cantarella S, Lamperi S. Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy. ASAIO Trans. 1988;34:635–639
  76. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis. 2003;41:1293–1302

PII: S0272-6386(07)01236-X

doi: 10.1053/j.ajkd.2007.08.015

American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 967-988 , December 2007

Article Tools

* Image Usage & Resolution